Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28834100 | 1.00 | EPHX2 (0.51) | EPHX2USP30BTKBRD4PIK3CD | |
| SCHEMBL28834101 | 1.00 | EPHX2 (0.51) | EPHX2USP30BTKBRD4PIK3CD | |
| SCHEMBL23359653 | 0.94 | EPHX2 (0.54) | EPHX2USP30NOS2 | |
| SCHEMBL28834155 | 0.91 | USP30 (0.49) | EPHX2USP30BTKPIK3CDCNR1 | |
| SCHEMBL29862661 | 0.91 | USP30 (0.49) | EPHX2USP30BTKPIK3CDCNR1 | |
| SCHEMBL28834238 | 0.91 | USP30 (0.49) | EPHX2USP30BTKPIK3CDCNR1 | |
| SCHEMBL28834157 | 0.91 | USP30 (0.49) | EPHX2USP30BTKPIK3CDCNR1 | |
| SCHEMBL29863210 | 0.91 | USP30 (0.49) | EPHX2USP30BTKPIK3CDCNR1 | |
| SCHEMBL28834242 | 0.90 | BRD4 (0.49) | EPHX2USP30BTKBRD4PIK3CD | |
| SCHEMBL28834244 | 0.90 | BRD4 (0.49) | EPHX2USP30BTKBRD4PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4055014-B1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORP (KR) | 2025-04-30 | — | — | EP | disclosed |
| CN-114867719-B | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2024-06-25 | — | — | CN | disclosed |
| US-11655235-B2 | Pyrrolidine and piperidine compounds | YUHAN CORPORATION (KR) | 2023-05-23 | — | — | US | disclosed |
| EP-4055014-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | Yuhan Corporation (KR) | 2022-09-14 | — | — | EP | disclosed |
| CN-114867719-A | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2022-08-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655235-B2 | Pyrrolidine and piperidine compounds | FAP, APC, VHL | EPHX2 2516/4885USP30 1231/4885BTK 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.